Suboptimal, inconsistent treatment for anaphylaxis due to unknown cause
A new Canadian study, led by a team at the Research Institute of the 麻豆AV Health Centre (RI-MUHC), is shedding light on anaphylaxis due to an unknown trigger (AUT)鈥攁n unpredictable and potentially fatal allergic reaction, about which surprisingly little is known.
, published in The Journal of Allergy and Clinical Immunology: In Practice, followed nearly 4,000 cases of anaphylaxis seen in Canadian emergency departments from 2011 to 2018. Common causes of anaphylaxis include food, medication, insect stings, latex and exercise, but in some episodes no definite cause can be determined. With food anaphylaxis, avoidance of the triggering food is a key principle of management; but with AUT, the possibility of a sudden life-threatening anaphylactic episode could occur at any time.
鈥淚n our study, 7.5 percent of the anaphylaxis cases were due to an unknown cause, and we found that the treatment and follow up of AUT were suboptimal and inconsistent both inside and outside of the hospital,鈥� says lead researcher Dr. Moshe Ben-Shoshan, a pediatric allergist and immunologist at the Research Institute of the 麻豆AV Health Centre (RI-MUHC), and the Montreal Children鈥檚 Hospital of the MUHC.
鈥淪pecifically, epinephrine was underused and antihistamines were the primary treatment drug for AUT: 46 percent of patients in our study received antihistamines before arriving at the hospital and 55 percent of patients received antihistamines in the hospital emergency department,鈥� adds Dr. Ben- Shoshan, who is also an assistant professor of Pediatrics at 麻豆AV.
This research is the first longitudinal, large-scale study to assess the clinical characteristics, treatment, and follow-up management of AUT cases across Canada. The study is part of a larger national project and database called the Cross-Canada Anaphylaxis Registry (C-CARE), which tracks the rates, triggers and management of anaphylaxis in different provinces and settings across Canada.
Among the study鈥檚 other findings:
- Nearly one-fifth of patients with AUT were not prescribed an epinephrine autoinjector;
- Adults were less likely to receive an epinephrine autoinjector prescription than children;
- Only 56 percent of patients with AUT were referred to an allergist, most of these were children;
- Of the patients assessed by an allergist, a trigger for their reaction was identified in 38 percent of cases.
鈥淭he underuse of epinephrine and the low rates of referral to an allergist, mainly in adults with AUT, highlight the need for clear guidelines and educational programs for diagnosis and management,鈥� says study first-author Michelle Le, a medical student at 麻豆AV and an AllerGen trainee.
鈥淭he important takeaway from this study is that there are significant discrepancies in treatment and follow up of patients with AUT that must be addressed in order to ensure prompt and appropriate management of anaphylaxis.鈥�
About AllerGen NCE Inc.
the Allergy, Genes and Environment Network (est. 2004), is a national research network dedicated to improving the quality of life of people suffering from allergic and related immune diseases. Funded by Industry Canada through the federal Networks of Centres of Excellence (NCE) Program, the Network is hosted at McMaster University in Hamilton.
About the Research Institute of the MUHC
The Research Institute of the 麻豆AV Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of 麻豆AV, is the research arm of the 麻豆AV Health Centre (MUHC) 鈥� an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,300 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC. Its research facilities offer a dynamic multidisciplinary environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan. The RI-MUHC is supported in part by the Fonds de recherche du Qu茅bec 鈥� Sant茅 (FRQS). .
